Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
Latest Information Update: 28 Jan 2025
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Mycosis fungoides
- Focus Therapeutic Use
Most Recent Events
- 05 Jul 2024 Planned End Date changed from 30 Jun 2024 to 30 Jan 2026.
- 05 Jul 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jan 2026.
- 14 Oct 2022 Status changed from not yet recruiting to recruiting.